Next Article in Journal
In Vitro Evaluation of a Phage Cocktail Controlling Infections with Escherichia coli
Next Article in Special Issue
Obstetric Outcomes of SARS-CoV-2 Infection in Asymptomatic Pregnant Women
Previous Article in Journal
Potentially Infectious Novel Hepatitis A Virus Strains Detected in Selected Treated Wastewater Discharge Sources, South Africa
Previous Article in Special Issue
ART-Treated Patients Exhibit an Adaptive Immune Response against the HFVAC Peptides, a Potential HIV-1 Therapeutic Vaccine (Provir/Latitude45 Study)
Review

HIV Vaccine Development: 35 Years of Experimenting in the Funding of Biomedical Research

Vaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rm 9C20B, Bethesda, MD 20892-9829, USA
Academic Editor: Herve J. A. Fleury
Viruses 2020, 12(12), 1469; https://doi.org/10.3390/v12121469
Received: 3 December 2020 / Revised: 16 December 2020 / Accepted: 17 December 2020 / Published: 19 December 2020
(This article belongs to the Special Issue HIV and SARS-CoV-2 Pathogenesis and Vaccine Development)
Funding vaccine development research is more complicated than simply putting out an announcement of funds available. The funders must decide whether product development can be accomplished by purely applied research, or whether more fundamental knowledge is needed before product development can be started. If additional basic knowledge is needed, identifying the specific area of the knowledge gap can be a challenge. Additionally, when there appears to be a clear path of applied research sometimes obstacles are encountered that require a return to more basic work. After deciding on the work to be done, funders must attract the scientists with the broad range of needed skills to cover all the stages of development. Collaborations must be promoted and alliances with other funders and industry must be developed. Funders use multiple tools and strategies to accomplish these tasks with varying success. View Full-Text
Keywords: HIV-1; HIV vaccines; vaccinology; vaccine design; biomedical research funding HIV-1; HIV vaccines; vaccinology; vaccine design; biomedical research funding
Show Figures

Figure 1

MDPI and ACS Style

Shapiro, S.Z. HIV Vaccine Development: 35 Years of Experimenting in the Funding of Biomedical Research. Viruses 2020, 12, 1469. https://doi.org/10.3390/v12121469

AMA Style

Shapiro SZ. HIV Vaccine Development: 35 Years of Experimenting in the Funding of Biomedical Research. Viruses. 2020; 12(12):1469. https://doi.org/10.3390/v12121469

Chicago/Turabian Style

Shapiro, Stuart Z. 2020. "HIV Vaccine Development: 35 Years of Experimenting in the Funding of Biomedical Research" Viruses 12, no. 12: 1469. https://doi.org/10.3390/v12121469

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop